Cholesterol in Alzheimer's disease

Lancet Neurology

Volumn 4, Issue 12, 2005, Pages 841-852

  Shobab, Leila A ^a   Hsiung, Ging Yuek R ^a   Feldman, Howard H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PLACEBO; SIMVASTATIN;

ALZHEIMER DISEASE; BRAIN METABOLISM; BRAIN TISSUE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG INDICATION; DRUG POTENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIVER TOXICITY; NEUROBLASTOMA; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; CHOLESTEROL; HUMANS; MODELS, BIOLOGICAL; RISK;

EID: 27744602604     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(05)70248-9     Document Type: Review

References (150)

1. E Von Strauss, M Viitanen, D De Ronchi, B Winblad, L Fratiglioni Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians Arch Neurol 56 1999 587 592
2. R Brookmeyer, S Gray, C Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337 1342
3. JC De la Torre Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics Lancet Neurol 3 2004 184 190
4. RN Kalaria Small vessel disease and Alzheimer's dementia: pathological considerations Cerebrovasc Dis 13 suppl 2 2002 48 52
5. SE Vermeer, PJ Koudstaal, M Oudkerk, A Hofman, MM Breteler Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study Stroke 33 2002 21 25
6. MM Breteler Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study Ann N Y Acad Sci 903 2000 457 465
7. JS Meyer, G Rauch, RA Rauch, A Haque Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia Neurobiol Aging 21 2000 161 169
8. T Linden, I Skoog, B Fagerberg, B Steen, C Blomstrand Cognitive impairment and dementia 20 months after stroke Neuroepidemiology 23 2004 45 52
9. RG Riekse, JB Leverenz, W McCormick Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study J Am Geriatr Soc 52 2004 1442 1448
10. M Sadowski, J Pankiewicz, H Scholtzova Links between the pathology of Alzheimer's disease and vascular dementia Neurochem Res 29 2004 1257 1266
11. M Kivipelto, EL Helkala, T Hanninen Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study Neurology 56 2001 1683 1689
12. MC Morris, DA Evans, JL Bienias Dietary fats and the risk of incident Alzheimer disease Arch Neurol 60 2003 194 200
13. IL Notkola, R Sulkava, J Pekkanen Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease Neuroepidemiology 17 1998 14 20
14. LM Refolo, MA Pappolla, J LaFrancois A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease Neurobiol Dis 8 2001 890 899
15. M Heverin, N Bogdanovic, D Lutjohann Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease J Lipid Res 45 2004 186 193
16. MA Wollmer, JR Streffer, D Lutjohann ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease Neurobiol Aging 24 2003 421 426
17. A Papassotiropoulos, D Lutjohann, M Bagli 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia J Psychiatr Res 36 2002 27 32
18. N Bogdanovic, L Bretillon, EG Lund On the turnover of brain cholesterol in patients with Alzheimer's disease: abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells Neurosci Lett 314 2001 45 48
19. P Schonknecht, D Lutjohann, J Pantel Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls Neurosci Lett 324 2002 83 85
20. H Jick, GL Zornberg, SS Jick, S Seshadri, DA Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
21. K Rockwood, S Kirkland, DB Hogan Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch Neurol 59 2002 223 227
22. B Wolozin, W Kellman, P Ruosseau, GG Celesia, G Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
23. K Yaffe, E Barrett-Connor, F Lin, D Grady Serum lipoprotein levels, statin use, and cognitive function in older women Arch Neurol 59 2002 378 384
24. PP Zandi, DL Sparks, AS Khachaturian Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study Arch Gen Psychiatry 62 2005 217 224
25. TD Rea, JC Breitner, BM Psaty Statin use and the risk of incident dementia: the Cardiovascular Health Study Arch Neurol 62 2005 1047 1051
26. G Li, R Higdon, WA Kukull Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study Neurology 63 2004 1624 1628
27. I Hajjar, J Schumpert, V Hirth, D Wieland, GP Eleazer The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment J Gerontol A Biol Sci Med Sci 57 2002 M414 M418
28. FW Pfrieger Cholesterol homeostasis and function in neurons of the central nervous system Cell Mol Life Sci 60 2003 1158 1171
29. J Poirier, A Baccichet, D Dea, S Gauthier Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats Neuroscience 55 1993 81 90
30. CK Mathews, KE van Holde, KG Ahern Biochemistry 3rd edn. 2000 Wesley Longman Inc San Fancisco
31. C Arnaud, F Mach Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation Arch Mal Coeur Vaiss 98 2005 661 666
32. JJ Nawarskas HMG-CoA reductase inhibitors and coenzyme Q10 Cardiol Rev 13 2005 76 79
33. H Paiva, KM Thelen, R Van Coster High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial Clin Pharmacol Ther 78 2005 60 68
34. B Wolozin A fluid connection: cholesterol and Abeta Proc Natl Acad Sci USA 98 2001 5371 5373
35. J Poirier Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease Trends Mol Med 9 2003 94 101
36. H Jurevics, P Morell Cholesterol for synthesis of myelin is made locally, not imported into brain J Neurochem 64 1995 895 901
37. NA Elshourbagy, WS Liao, RW Mahley, JM Taylor Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets Proc Natl Acad Sci USA 82 1985 203 207
38. AM Fagan, DM Holtzman Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo Microsc Res Tech 50 2000 297 304
39. O Combarros, J Infante, J Llorca, J Berciano Genetic association of CYP46 and risk for Alzheimer's disease Dement Geriatr Cogn Disord 18 2004 257 260
40. A Papassotiropoulos, D Lutjohann, M Bagli Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease Neuroreport 11 2000 1959 1962
41. H Kolsch, R Heun, A Kerksiek Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients Neurosci Lett 368 2004 303 308
42. L Liu, AE Bortnick, M Nickel Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles J Biol Chem 278 2003 42976 42984
43. RR Singaraja, C Fievet, G Castro Increased ABCA1 activity protects against atherosclerosis J Clin Invest 110 2002 35 42
44. KY Zwarts, SM Clee, AH Zwinderman ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels Clin Genet 61 2002 115 125
45. T Kyriakou, C Hodgkinson, DE Pontefract Genotypic effect of the -565C→T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis Arterioscler Thromb Vasc Biol 25 2005 418 423
46. RP Koldamova, IM Lefterov, MD Ikonomovic 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion J Biol Chem 278 2003 13244 13256
47. V Hirsch-Reinshagen, S Zhou, BL Burgess Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain J Biol Chem 279 2004 41197 41207
48. SE Wahrle, H Jiang, M Parsadanian ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE J Biol Chem 279 2004 40987 40993
49. S Ohtsuki, Y Watanabe, S Hori mRNA expression of the ATP-binding cassette transporter subfamily A (ABCA) in rat and human brain capillary endothelial cells Biol Pharm Bull 27 2004 1437 1440
50. U Panzenboeck, Z Balazs, A Sovic ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells J Biol Chem 277 2002 42781 42789
51. M Ujiie, DL Dickstein, DA Carlow, WA Jefferies Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model Microcirculation 10 2003 463 470
52. M Heverin, S Meaney, D Lutjohann Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain J Lipid Res 46 2005 1047 1052
53. D Lutjohann, O Breuer, G Ahlborg Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation Proc Natl Acad Sci USA 93 1996 9799 9804
54. V Leoni, T Masterman, P Patel Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers J Lipid Res 44 2003 793 799
55. D Lutjohann, A Papassotiropoulos, I Bjorkhem Plasma 24S- hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients J Lipid Res 41 2000 195 198
56. S Locatelli, D Lutjohann, HH Schmidt Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain Arch Neurol 59 2002 213 216
57. V Leoni, T Masterman, FS Mousavi Diagnostic use of cerebral and extracerebral oxysterols Clin Chem Lab Med 42 2004 186 191
58. LM Refolo, B Malester, J LaFrancois Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model Neurobiol Dis 7 2000 321 331
59. FS Shie, LW Jin, DG Cook, JB Leverenz, RC LeBoeuf Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice Neuroreport 13 2002 455 459
60. DL Sparks, YM Kuo, A Roher, T Martin, RJ Lukas Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations Ann N Y Acad Sci 903 2000 335 344
61. E Kojro, G Gimpl, S Lammich, W Marz, F Fahrenholz Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10 Proc Natl Acad Sci USA 98 2001 5815 5820
62. M Simons, P Keller, B De Strooper Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons Proc Natl Acad Sci USA 95 1998 6460 6464
63. S Wahrle, P Das, AC Nyborg Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains Neurobiol Dis 9 2002 11 23
64. M Racchi, R Baetta, N Salvietti Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content Biochem J 322 1997 893 898
65. S Bodovitz, WL Klein Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein J Biol Chem 271 1996 4436 4440
66. W Gibson Wood, GP Eckert, U Igbavboa, WE Muller Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease Biochim Biophys Acta 1610 2003 281 290
67. H Hayashi, U Igbavboa, H Hamanaka Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice Neuroreport 13 2002 383 386
68. U Igbavboa, NA Avdulov, F Schroeder, WG Wood Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice J Neurochem 66 1996 1717 1725
69. C Kirsch, GP Eckert, WE Mueller Statin effects on cholesterol micro-domains in brain plasma membranes Biochem Pharmacol 65 2003 843 856
70. K Zou, D Kim, A Kakio Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain J Neurochem 87 2003 609 619
71. J McLaurin, AA Darabie, MR Morrison Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis Pharmacopsychiatry 36 suppl 2 2003 S130 S135
72. PG Pentchev, EJ Blanchette-Mackie, EA Dawidowicz The NP-C gene: a key to pathways of intracellular cholesterol transport Trends Cell Biol 4 1994 365 369
73. MT Vanier, G Millat Niemann-Pick disease type C Clin Genet 64 2003 269 281
74. MG Spillantini, M Tolnay, S Love, M Goedert Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia Acta Neuropathol (Berl) 97 1999 585 594
75. Y Saito, K Suzuki, CM Hulette, S Murayama Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease J Neuropathol Exp Neurol 63 2004 323 328
76. R Distl, V Meske, TG Ohm Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons Acta Neuropathol (Berl) 101 2001 547 554
77. R Distl, S Treiber-Held, F Albert Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain J Pathol 200 2003 104 111
78. IA Auer, ML Schmidt, VM Lee Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease Acta Neuropathol (Berl) 90 1995 547 551
79. N Girardot, B Allinquant, D Langui Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease Neuropathol Appl Neurobiol 29 2003 451 461
80. AR Koudinov, NV Koudinova Cholesterol homeostasis failure as a unifying cause of synaptic degeneration J Neurol Sci 229-230 2005 233 240
81. V Meske, F Albert, D Richter, J Schwarze, TG Ohm Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease Eur J Neurosci 17 2003 93 102
82. QW Fan, W Yu, T Senda, K Yanagisawa, M Michikawa Cholesterol-dependent modulation of tau phosphorylation in cultured neurons J Neurochem 76 2001 391 400
83. A Hofman, A Ott, MM Breteler Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet 349 1997 151 154
84. DA Snowdon, LH Greiner, JA Mortimer Brain infarction and the clinical expression of Alzheimer disease: the Nun Study JAMA 277 1997 813 817
85. JA Nicoll, C Burnett, S Love High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy Ann Neurol 41 1997 716 721
86. HC O'Donnell, J Rosand, KA Knudsen Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage N Engl J Med 342 2000 240 245
87. DM Holtzman, AM Fagan, B Mackey Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model Ann Neurol 47 2000 739 747
88. RB DeMattos Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease J Mol Neurosci 23 2004 255 262
89. B Urmoneit, I Prikulis, G Wihl Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy Lab Invest 77 1997 157 166
90. M Christoforidis, R Schober, K Krohn Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy Neuropathol Appl Neurobiol 31 2005 11 19
91. M Kivipelto, EL Helkala, MP Laakso Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease Ann Intern Med 137 2002 149 155
92. GP Jarvik, EM Wijsman, WA Kukull Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study Neurology 45 1995 1092 1096
93. MA Pappolla, TK Bryant-Thomas, D Herbert Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology Neurology 61 2003 199 205
94. RA Whitmer, S Sidney, J Selby, SC Johnston, K Yaffe Midlife cardiovascular risk factors and risk of dementia in late life Neurology 64 2005 277 281
95. MC Morris, DA Evans, JL Bienias Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease Arch Neurol 60 2003 940 946
96. S Kalmijn, LJ Launer, A Ott Dietary fat intake and the risk of incident dementia in the Rotterdam Study Ann Neurol 42 1997 776 782
97. P Barberger-Gateau, L Letenneur, V Deschamps Fish, meat, and risk of dementia: cohort study Bmj 325 2002 932 933
98. JA Luchsinger, R Mayeux Dietary factors and Alzheimer's disease Lancet Neurol 3 2004 579 587
99. TA Mori, LJ Beilin Omega-3 fatty acids and inflammation Curr Atheroscler Rep 6 2004 461 467
100. CN Serhan Novel omega-3-derived local mediators in anti-inflammation and resolution Pharmacol Ther 105 2005 7 21
101. WE Connor, CA DeFrancesco, SL Connor N-3 fatty acids from fish oil: effects on plasma lipoproteins and hypertriglyceridemic patients Ann N Y Acad Sci 683 1993 16 34
102. EH Corder, AM Saunders, WJ Strittmatter Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
103. DC Rubinsztein, DF Easton Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis Dement Geriatr Cogn Disord 10 1999 199 209
104. H Kolsch, D Lutjohann, M Ludwig Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease Mol Psychiatry 7 2002 899 902
105. P Desai, ST DeKosky, MI Kamboh Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease Neurosci Lett 328 2002 9 12
106. A Papassotiropoulos, JR Streffer, M Tsolaki Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism Arch Neurol 60 2003 29 35
107. A Johansson, H Katzov, H Zetterberg Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease Hum Genet 114 2004 581 587
108. H Katzov, K Chalmers, J Palmgren Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism Hum Mutat 23 2004 358 367
109. Y Li, K Tacey, L Doil Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study Neurosci Lett 366 2004 268 271
110. M Causevic, N Ramoz, V Haroutunian, KL Davis, JD Buxbaum Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype J Neuropathol Exp Neurol 62 2003 999 1005
111. H Kolsch, U Ptok, I Mohamed Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease Am J Med Genet B Neuropsychiatr Genet 121 2003 128 130
112. M Sanchez-Guerra, O Combarros, J Infante Case-control study and meta-analysis of low density lipoprotein receptor-related protein gene exon 3 polymorphism in Alzheimer's disease Neurosci Lett 316 2001 17 20
113. CL Lendon, CJ Talbot, NJ Craddock Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population Neurosci Lett 222 1997 187 190
114. K Murakami, M Shimizu, N Yamada Apolipoprotein E polymorphism is associated with plasma cholesterol response in a 7-day hospitalization study for metabolic and dietary control in NIDDM Diabetes Care 16 1993 564 569
115. M Eto, K Watanabe, N Chonan, K Ishii Familial hypercholesterolemia and apolipoprotein E4 Atherosclerosis 72 1988 123 128
116. K Luthra, M Tripathi, R Grover Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia Dement Geriatr Cogn Disord 17 2004 132 135
117. NR Graff-Radford, RC Green, RC Go Association between apolipoprotein E genotype and Alzheimer disease in African American subjects Arch Neurol 59 2002 594 600
118. GY Hsiung, AD Sadovnick, H Feldman Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging CMAJ 171 2004 863 867
119. R Mayeux, Y Stern, R Ottman The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease Ann Neurol 34 1993 752 754
120. AM Saunders, AD Roses Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease Stroke 24 1993 1416 1417
121. AJ Slooter, M Cruts, S Kalmijn Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study Arch Neurol 55 1998 964 968
122. CL Lendon, JM Harris, AL Pritchard Genetic variation of the APOE promoter and outcome after head injury Neurology 61 2003 683 685
123. GM Teasdale, JA Nicoll, G Murray, M Fiddes Association of apolipoprotein E polymorphism with outcome after head injury Lancet 350 1997 1069 1071
124. B Borroni, S Archetti, C Agosti Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators Neurobiol Aging 25 2004 747 751
125. A Kabbara, N Payet, D Cottel Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population Neurosci Lett 363 2004 139 143
126. M Ingelsson, J Jesneck, MC Irizarry, BT Hyman, GW Rebeck Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease Neurosci Lett 367 2004 228 231
127. D Fallin, A Kundtz, T Town No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample Neurosci Lett 233 1997 145 147
128. K Fassbender, M Simons, C Bergmann Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc Natl Acad Sci USA 98 2001 5856 5861
129. JD Buxbaum, NS Geoghagen, LT Friedhoff Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide J Alzheimers Dis 3 2001 221 229
130. S Parvathy, M Ehrlich, S Pedrini Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding J Neurochem 90 2004 1005 1010
131. D Paris, KP Townsend, J Humphrey Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae Atherosclerosis 161 2002 293 299
132. YX Sun, M Crisby, S Lindgren, S Janciauskiene Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Abeta(1-42) in glioma cell culture in vitro Pharmacol Res 47 2003 119 126
133. H Osamah, R Mira, S Sorina, K Shlomo, A Michael Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets Br J Clin Pharmacol 44 1997 77 83
134. E Ongini, F Impagnatiello, A Bonazzi Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties Proc Natl Acad Sci USA 101 2004 8497 8502
135. O Grip, S Janciauskiene, S Lindgren Pravastatin down-regulates inflammatory mediators in human monocytes in vitro Eur J Pharmacol 410 2000 83 92
136. J Haendeler, J Hoffmann, AM Zeiher, S Dimmeler Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins Circulation 110 2004 856 861
137. JK Liao Isoprenoids as mediators of the biological effects of statins J Clin Invest 110 2002 285 288
138. S Kinlay, GG Schwartz, AG Olsson High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566
139. J Chen, ZG Zhang, Y Li Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Ann Neurol 53 2003 743 751
140. G Tringali, M Vairano, C Dello Russo, P Preziosi, P Navarra Lovastatin and mevastatin reduce basal and cytokine-stimulated production of prostaglandins from rat microglial cells in vitro: evidence for a mechanism unrelated to the inhibition of hydroxy-methyl-glutaryl CoA reductase Neurosci Lett 354 2004 107 110
141. D Lutjohann, M Stroick, T Bertsch High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs Steroids 69 2004 431 438
142. NB Chauhan, GJ Siegel, DL Feinstein Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain Neurochem Res 29 2004 1897 1911
143. GL Vega, MF Weiner, AM Lipton Reduction in levels of 24S- hydroxycholesterol by statin treatment in patients with Alzheimer disease Arch Neurol 60 2003 510 515
144. M Simons, F Schwarzler, D Lutjohann Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial Ann Neurol 52 2002 346 350
145. K Hoglund, KM Thelen, S Syversen The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease Dement Geriatr Cogn Disord 19 2005 256 265
146. M Sjogren, K Gustafsson, S Syversen Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein Dement Geriatr Cogn Disord 16 2003 25 30
147. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
148. J Shepherd, GJ Blauw, MB Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
149. DL Sparks, MN Sabbagh, DJ Connor Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results Arch Neurol 62 2005 753 757
150. LR Wagstaff, MW Mitton, BM Arvik, PM Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880